pLentiCRISPR-mCherry Citations (7)
Originally described in: Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL.McComb S, Aguade-Gorgorio J, Harder L, Marovca B, Cario G, Eckert C, Schrappe M, Stanulla M, von Stackelberg A, Bourquin JP, Bornhauser BC Sci Transl Med. 2016 May 18;8(339):339ra70. doi: 10.1126/scitranslmed.aad2986. PubMed Journal
Articles Citing pLentiCRISPR-mCherry
| Articles |
|---|
| Fenretinide induces a new form of dynamin-dependent cell death in pediatric sarcoma. Brack E, Wachtel M, Wolf A, Kaech A, Ziegler U, Schafer BW. Cell Death Differ. 2020 Aug;27(8):2500-2516. doi: 10.1038/s41418-020-0518-z. Epub 2020 Mar 6. PubMed |
| BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer. Shahbandi A, Rao SG, Anderson AY, Frey WD, Olayiwola JO, Ungerleider NA, Jackson JG. Cell Death Differ. 2020 May 26. pii: 10.1038/s41418-020-0564-6. doi: 10.1038/s41418-020-0564-6. PubMed |
| Efficient Generation of Multi-gene Knockout Cell Lines and Patient-derived Xenografts Using Multi-colored Lenti-CRISPR-Cas9. Behrmann L, McComb S, Aguade-Gorgorio J, Huang Y, Hermann M, Pelczar P, Aguzzi A, Bourquin JP, Bornhauser BC. Bio Protoc. 2017 Apr 5;7(7):e2222. doi: 10.21769/BioProtoc.2222. eCollection 2017 Apr 5. PubMed |
In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target.
Wang X, Tokheim C, Gu SS, Wang B, Tang Q, Li Y, Traugh N, Zeng Z, Zhang Y, Li Z, Zhang B, Fu J, Xiao T, Li W, Meyer CA, Chu J, Jiang P, Cejas P, Lim K, Long H, Brown M, Liu XS.
Cell. 2021 Oct 14;184(21):5357-5374.e22. doi: 10.1016/j.cell.2021.09.006. Epub 2021 Sep 27.
PubMed
Associated Plasmids |
| Phosphoinositide species and filamentous actin formation mediate engulfment by senescent tumor cells. Frey WD, Anderson AY, Lee H, Nguyen JB, Cowles EL, Lu H, Jackson JG. PLoS Biol. 2022 Oct 24;20(10):e3001858. doi: 10.1371/journal.pbio.3001858. eCollection 2022 Oct. PubMed |
CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models.
Timpanaro A, Piccand C, Dzhumashev D, Anton-Joseph S, Robbi A, Moser J, Rossler J, Bernasconi M.
J Exp Clin Cancer Res. 2023 Nov 4;42(1):293. doi: 10.1186/s13046-023-02838-3.
PubMed
Associated Plasmids |
| Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic target. Breunis W, Brack E, Ehlers AC, Bechtold I, Kisele S, Wurth J, Mous L, Zabele D, Steffen F, Zahnow F, Britschgi C, Bankel L, Rothermundt C, Vetter C, Muller D, Botter S, Pauli C, Bode P, Rinner B, Bourquin JP, Roessler J, Grunewald TGP, Schafer BW, Surdez D, Wachtel M. Nat Commun. 2025 Aug 21;16(1):7688. doi: 10.1038/s41467-025-62629-6. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.